NasdaqHealth CareHealth Care EquipmentS&P MidCap 400
$89.99
-1.15 (-1.26%)
Close of Nov 06, 2026 · end-of-day data
LIVN 8-K filings in 2026
Every material Form 8-K LivaNova filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
LivaNova reported third-quarter 2026 revenue of $393.1 million, up 9.9% from a year earlier, and raised its full-year 2026 constant-currency revenue growth range to 9% to 10% and its adjusted diluted EPS range to $4.40 to $4.50. GAAP diluted EPS fell to $0.11 from $0.49, reflecting $34.0 million of other operating expense, so shareholders face a mix of stronger underlying results and a lower reported profit.
Q3 2026 revenue was $393.1 million, up 9.9% reported and 10.0% constant-currency; Cardiopulmonary rose 10.9% and Neuromodulation rose 11.1%.
Q3 2026 GAAP diluted EPS was $0.11 versus $0.49 a year earlier; adjusted diluted EPS was $1.23 versus $1.11.
Full-year 2026 constant-currency revenue growth guidance rose to 9% to 10% from 8% to 9%.
Full-year 2026 adjusted diluted EPS guidance rose to $4.40 to $4.50 from $4.30 to $4.40; adjusted free cash flow guidance of $140 million to $160 million was maintained.
LivaNova reported second-quarter 2026 revenue of $390.6 million, up 10.8% from a year earlier, and adjusted diluted EPS of $1.26 versus $1.05. It raised its full-year 2026 revenue growth and adjusted EPS guidance but lowered its adjusted free cash flow guidance to $140 million to $160 million. For shareholders, the results show top-line and adjusted profit growth alongside a lower cash flow outlook, and GAAP operating income declined.
Q2 2026 revenue was $390.6 million, up 10.8% reported and 9.8% constant-currency, from $352.5 million in Q2 2025.
GAAP diluted EPS was $1.93 versus $0.50, including a discrete tax benefit of $95.4 million from an Italian tax authority ruling; adjusted diluted EPS was $1.26 versus $1.05.
GAAP operating income was $49.5 million versus $54.2 million a year earlier; adjusted operating income was $90.8 million versus $77.4 million.
2026 guidance: constant-currency revenue growth raised to 8% to 9% (from 7% to 8%) and adjusted EPS raised to $4.30 to $4.40 (from $4.20 to $4.30); adjusted free cash flow lowered to $140 million to $160 million (from $160 million to $180 m
LivaNova reported first-quarter 2026 revenue of $362.3 million, up 14.3% from a year earlier, and raised its full-year 2026 revenue and adjusted diluted earnings per share guidance. GAAP diluted EPS was $0.40, compared with a loss of $6.01 a year earlier that included a $360.4 million SNIA environmental liability expense, and adjusted diluted EPS rose to $0.98 from $0.88.
Q1 revenue of $362.3 million rose 14.3% reported and 11.1% in constant currency; Cardiopulmonary revenue rose 18.3%.
GAAP diluted EPS was $0.40 versus a loss of $6.01 in Q1 2025; adjusted diluted EPS was $0.98 versus $0.88.
2026 adjusted diluted EPS guidance raised to $4.20 to $4.30 from $4.15 to $4.25; revenue growth guidance raised to 7.0% to 8.0% from 6.0% to 7.0% in constant currency.
FDA granted premarket approval for the aura6000 System for moderate to severe obstructive sleep apnea.
LivaNova reported fourth-quarter and full-year 2025 results and issued 2026 guidance. Full-year revenue rose 10.7% to $1.39 billion and adjusted diluted EPS reached $3.90, but a $365.6 million SNIA environmental liability expense produced a GAAP diluted loss of $4.45 per share. The company expects 2026 adjusted diluted EPS of $4.15 to $4.25, which sets the earnings outlook shareholders will track in the coming year.
Fourth-quarter 2025 revenue was $360.9 million, up 12.1% on a reported basis; GAAP diluted EPS was $0.56 versus $1.02, and adjusted diluted EPS was $0.86 versus $0.81.
Full-year 2025 revenue was $1.39 billion, up 10.7%; GAAP diluted loss was $4.45 per share, including the $365.6 million SNIA charge, and adjusted diluted EPS was $3.90 versus $3.38.
2026 guidance calls for constant-currency revenue growth of 6.0% to 7.0%, adjusted diluted EPS of $4.15 to $4.25, and adjusted free cash flow of $160 million to $180 million.
Increased CMS reimbursement for VNS Therapy for drug-resistant epilepsy takes effect January 1, 2026, with hospital outpatient payments rising about 48% for new patient implants.
LivaNova PLC said its Senior Vice President, Chief Legal Officer and Company Secretary, Michael Hutchinson, resigned on January 12, 2026 to pursue another opportunity. The company plans to hire an external search firm to find a successor, and the filing does not name an interim replacement.
Michael Hutchinson resigned as SVP, Chief Legal Officer and Company Secretary, notified January 12, 2026
His last day with LivaNova is January 26, 2026
The company expects to retain an external search firm to find a new Chief Legal Officer
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every LivaNova filing is on SEC EDGAR ↗. 8-K briefs of other companies →